Inbiomotion's Series B Round

Inbiomotion raised a round of funding on March 14, 2016.

Inbiomotion, founded in 2012, develops diagnostic tests for predicting the risk that cancer patients may suffer bone metastasis. The target market is patients with prostate or breast cancer, where bon…

Articles about Inbiomotion's Series B Round: